A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight

Inclusion Criteria:

• Male or female

• Age above or equal to 18 years at the time of signing informed consent

1. Body Mass Index (BMI) greater than or equal to 30.0 kilograms per square meter (kg/m^2) or

2. BMI greater than or equal to 27.0 kg/m^2 with the presence of at least oneweight-related comorbidity including, but not limited to, type 2 diabetesmellitus, hypertension, dyslipidaemia, obstructive sleep apnoea orcardiovascular disease

For participants with Type 2 diabetes (T2D) at screening the following criteria also apply:

• Diagnosed with type 2 diabetes mellitus greater than equal to 180 days beforescreening

• Treatment with either lifestyle intervention, or treatment with 1-3 marketed oralantidiabetic drugs (OADs) (metformin, α-glucosidase inhibitors (AGI), glinides,sodium-glucose cotransporter 2 inhibitor (SGLT2i)), thiazolidinediones, orsulphonylureas (SUs) as a single agent or in combination) according to local label

• Treatment with oral antidiabetic drugs should be stable (same drug(s), dose anddosing frequency) for at least 60 days before screening

• Glycated Haemoglobin (HbA1c) 7 percent-10 percent (53-86 millimoles per mole [mmol/mol]) (both inclusive) as measured by the central laboratory at screening

Exclusion Criteria:

For participants without T2D at screening:

• HbA1c greater than or equal to 6.5 percent (48 mmol/mol) as measured by the centrallaboratory at screening

• History of type 1 or type 2 diabetes mellitus

For participants with T2D at screening:

• Clinically significant or severe hypoglycaemia within 6 months before screening orhistory of hypoglycaemia unawareness

• Renal impairment with estimated glomerular filtration rate (eGFR) lesser than 30milli liter per min/1.73 meter square (mL/min/1.73 m^2), as measured by the centrallaboratory at screening

• Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verifiedby a fundus examination performed within 90 days before screening or in the periodbetween screening and randomisation. Pharmacological pupil-dilation is a requirementunless using a digital fundus photography camera specified for non-dilatedexamination